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Copyright © 2008 JCBN Summary Bofutsushosan (BOF), an oriental herbal medicine, has been used as an anti-
obesity drug in overweight patients. In the present study, to evaluate the anti-obesity and
anti-diabetic effects of BOF, we investigated the effects of BOF on the white adipose tissue
(WAT) weight, the size of adipocytes, adiponectin expression, and oral glucose tolerance test
results in high-fat diet-fed male KK/Ta mice. In addition, the mRNA expression levels of
uncoupling protein 1 (UCP1) and UCP2 mRNA in WAT and brown adipose tissue (BAT) were
measured. 6-week-old KK/Ta mice were divided into four groups and fed a purified powdered
basal diet (the BD group), a purified high-fat (HF) powdered diet containing suet powder at
37.5 g/100 g diet (the HF group), a high-fat diet plus 1.0% bofutsushosan (BOF) treatment (the
HF + BOF group), or a high-fat diet plus 1.0% daisaikoto (DAI) treatment (the HF + DAI
group) for 4 weeks. The weight of WAT and the size of adipocytes were increased in the HF
group compared with those in the BD group, and these increases in the HF group were
significantly inhibited in the HF + BOF group, but not affected in the HF + DAI group. There
were no statistically significant differences in plasma levels and tissue mRNA levels of
adiponectin among the four groups. There were no significant differences in UCP1 mRNA
expression of BAT among the four groups. The expression of UCP1 mRNA in WAT was found
in the HF + BOF group, but little expression was seen in the WAT of the BD, HF, or HF + DAI
groups. The elevated plasma glucose levels and responses after the glucose loading in the HF
group tended to decrease in the HF + BOF group. These results suggest that BOF decreases
the weight and size gains of WAT along with up-regulating UCP1 mRNA in WAT in high-fat
diet-fed mice.
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Introduction
Obesity, which is characterized by excess accumulation of
adipose tissue, is the most common risk factor for metabolic
syndrome, a cluster of several abnormalities including
dyslipidemia, insulin resistance, type 2 diabetes, hyper-
tension, and atherosclerosis [1–3]. Although the molecular
pathways that link obesity with such a wide spectrum of
conditions are not well understood, recent studies have
indicated that adipose tissue plays a central role of in the
development of this syndrome [4–6]. Accumulating evidence
suggests that adipose tissue is not simply an inert energy
storage depot but also functions as a major endocrine organ,
producing and releasing a variety of bioactive substances,
especially adiponectin, into the bloodstream [7].
Recently, we developed a mouse model of metabolic
syndrome, in which an increase in visceral adipose tissue
precedes the development of fatty liver and insulin resis-
tance in high-fat diet-fed male KK/Ta mice [8]. Using this
experimental model, we sought to investigate the efficacy of
traditional Chinese drugs and formulations (Kampo formu-
lations) in the prevention of obesity. The first aim of the
present study was to investigate the preventive effects of
Bofutsushosan (BOF) and Daisaikoto (DAI) on the contents
and functions of visceral adipose tissues. BOF contains 18
components (Table 1) and has been used for the prevention
of obesity, hypertension, and insulin resistance [9]. The
anti-obesity action of BOF was first reported in mono-
sodium-L-glutamate-induced obese mice [10]. Yoshida et al.
[10] have demonstrated that white adipose tissue (WAT)
weight was decreased and guanosine-5'-diphosphate (GDP)
binding activity, an index of brown adipose tissue (BAT)
activation, was increased in mice treated with BOF in a
dose-dependent manner, and have concluded that BOF
works by activating the BAT thermogenesis and inhibiting
the phosphodiesterase activity in mice. DAI contains eight
components and has been used as a hypocholesterolemic
agent for liver disorders and as a therapeutic and preventive
agent for cholesterol gallstone disease [11]. In addition, DAI
does not contain ephedrine, a β-3 adrenoreceptor agonist,
which is found in BOF [10]. Therefore, we compared the
effects of these two Kampo medicines on the obesity in mice
in the present study.
Recent investigations have focused on adaptive thermo-
genesis by uncoupling protein (UCP) families (UCP1,
UCP2, and UCP3) as a physiological defense against
obesity, hyperlipidemia, and diabetes [12–14]. UCP-1
expression in BAT is known to be a significant component
of whole body energy expenditure and its dysfunction
contributes to the development of obesity [15]. However,
adult humans have very little BAT and most of their fat is
stored in WAT. Therefore, several studies have shown that
_3-adrenoreceptor agonists and some dietary constituents
induce expression of UCP1 not only in BAT, but also in
WAT [16–18]. Indeed, UCP1 expression in WAT can lead to
an increase in energy expenditure via the generation of heat.
Thus the second aim of the present study was to investigate
the effect of BOF and DAI on the mRNA expression of
UCP1 and UCP2 in the BAT and WAT in high-fat diet-fed
mice.
Materials and Methods
Animals and treatment
Male KK/Ta Jcl mice (5 weeks old, 18–20 g body weight)
were purchased from CLEA Japan Inc. (Tokyo, Japan). The
mice were individually housed in plastic cages at 24 ± 2ºC
and 45 ± 5% relative humidity with a 12/12-h light/dark
Table 1. Components of Kampo medicines (Chinese herbal
preparations)
a Each value (g) was represented as dry weight.
Bofu-tsusho-san (BOF): 4.5 g of a water extract of the following 
raw materialsa
1 Scutellariae Radix (Labiatae) 2.0
2 Glycyrrhizae Radix (Leguminosae) 2.0
3 Platycodi Radix (Campanulaceae) 2.0
4 Atractyloidis Lanceae Rhizoma (Compositae) 2.0
5 Rhei Rhizoma (Polygonaceae) 1.5
6 Schizonepetae Spica (Labiatae) 1.2
7 Gardeniae Fructus (Rubiaceae) 1.2
8 Paeonia Ragix (Paeoniaceae) 1.2
9 Cnidii Rhizoma (Umbelliferae) 1.2
10 Angelicae Radix (Umbelliferae) 1.2
11  Menthae Folium (Labiatae) 1.2
12 Saposhnikoviae Radix 1.2
13 Ephedrae herba (Ephedraceae) 1.2
14 Forsythiae Fructus 1.2
15 Zingiberis Rhizoma (Zingiberaceae) 0.3
16 Kaolinum 3.0
17 Gypsum Fibrosum 2.0
18 Natrium Sulfricum 0.7
Dai-saiko-to (DAI): 4.5 g of a water extract of the following raw 
materialsa
1 Bupleuri Radix (Umbelliferae) 6.0
2 Pinelliae Tuber (Araceae) 4.0
3 Scutellariae Radix (Labiatae) 3.0
4 Paeonia Ragix (Paeoniaceae) 3.0
5 Zizypus Fructus (Rhamnaceae) 3.0
6 Aurantii Fructus Immaturus (Rutaeae) 2.0
7 Zingiberis Rhizoma (Zingiberaceae) 1.0
8 Rhei Rhizoma (Polygonaceae) 1.0S. Akagiri et al.
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cycle, and were given free access to food and water
throughout the experimental period. After acclimation for 1
week by feeding with a basal diet (BD), 6-week-old KK/Ta
mice were divided into four groups of five mice each by
body weight and blood glucose level, and fed a purified
powdered diet (the BD group), a purified high-fat (HF)
powdered diet containing suet powder at 37.5 g/100 g diet
(the HF group), a high-fat diet plus bofutsushosan (BOF)
treatment (the HF + BOF group), or a high-fat diet plus
daisaikoto (DAI) treatment (the HF + DAI group) (Table 2).
After treatment with the experimental diet for 4 weeks,
starved animals were sacrificed under anesthesia with
intraperitoneal injection of sodium pentobarbital {Nembutal®
(Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan),
50 mg/kg of body weight} to collect blood, BAT, perirenal,
epididymal, mesenteric and inguinal WAT, and liver tissue.
All animal experiments and care were conducted in
conformity with the Guidelines of the Animal Care and Use
Committee of Kyoto Prefectural University of Medicine.
Oral glucose tolerance test and determination of plasma
glucose, insulin, lipids, and adiponectin
The oral glucose tolerance test (OGTT) was performed
before and 4-, 8- and 16-weeks after the treatment after
overnight fasting. The mice received a 20% glucose solution
(2 g/kg). Blood samples were collected just before and 0.5,
1, and 2 h after glucose loading. The rise in plasma glucose
concentrations was quantitated by the incremental area
under the curve (AUC glucose) for plasma glucose [19].
Plasma glucose levels were determined with a Glutest Ace R
(Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan).
Plasma adiponectin levels were measured using a mouse
adiponectin enzyme-linked immunosorbent assay (ELISA)
kit (Ohtsuka, Ltd., Tokyo, Japan). Asparate 2-oxoglutarate
aminotransferase (AST), alanine 2-oxoglutarate amino-
transferase (ALT), BUN, free cholesterol, triglyceride, non-
esterified fatty acid, and LDL-cholesterol were measured
with a Shimadzu CL8000 Clinical Chemistry Analyzer
(Shimadzu, Ltd., Tokyo, Japan).
Histological analysis
Small pieces of epididymal white adipose tissues and
liver were removed and rinsed with saline. The tissues were
fixed with 10% formalin and embedded in paraffin. Tissue
sections were cut at a thickness of 2.5 µm and stained with
hematoxylin and eosin. To examine the size of the white
adipocytes, the area of each adipocyte was measured in 40
cells of representative sections with Image J software
(National Institutes of Health, Bethesda, MD). The mean
value was designated as an index of the cell size.
mRNA analysis
Mouse BAT and epididymal WAT were taken and stored
in an Isogen solution (Nippon Gene Co., Ltd., Tokyo,
Japan). The mRNA expression of adiponectin and of
GAPDH as an internal control in the adipose tissue was
determined by real-time polymerase chain reaction (PCR).
Total RNA was isolated from adipose tissue by the acid
guanidinium phenol chloroform method with an Isogen kit
(Nippon Gene Co., Ltd) and the concentration of RNA was
determined by absorbance at 260 nm in relation to that at
280 nm. The isolated RNA was stored at 70°C until use in
real-time PCR. For the real-time PCR for adiponectin,
UCP-1, and -2, 1 µg of extracted RNA was reverse-
transcribed into first-strand complementary DNA (cDNA)
at 42°C for 40 min, using 200 U of M-MLV reverse-
transcriptase (Promega Corporation, Madison, WI) and
0.5 µg of oligo (dT) 15 primer (Takara Bio Inc., Shiga,
Japan) in a 20 µl reaction mixture. The real-time PCR for
adiponectin, UCP-1, and -2 was carried out with a 7300
Real-Time PCR system (Applied Biosystems, Foster City,
CA) using the DNA-binding dye SYBER Green I for the
Table 2. Composition of the experimental diet
Basal diet High-fat (HF) HF + BOF HF + DAI
w/w (%)
Milk casein 20.0000 24.4800 24.4800 24.4800
DL-methionine 0.3000 0.3672 0.3672 0.3672
Corn starch 14.6625 5.9294 5.6994 5.6994
Granulated sugar 49.0875 19.8506 19.0806 19.0806
Cellulose 5.0000 6.1200 6.1200 6.1200
Suet powder 6.2500 37.5000 37.5000 37.5000
Vitamin mix (AIN-76) 1.0000 1.2240 1.2240 1.2240
Mineral mix (AIN-76) 3.5000 4.2840 4.2840 4.2840
Choline bitartrate 0.2000 0.2448 0.2448 0.2448
Bofutsusyo-san 1.0000
Daisaiko-to 1.0000Bofutsushosan and Obesity
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detection of PCR products. The reaction mixture contained
12.5 µl Premix Ex Taq and 0.5 µl ROX reference dye
(Code RRO41A; Takara Bio Inc.), 1 µl custom-synthesized
primers, and 2 µl cDNA (equivalent to 20 ng total RNA) to
give a final reaction volume of 25 µl. The PCR settings were
as follows: the initial denaturation for 15 s at 95ºC was
followed by 40 cycles of amplification for 15 s at 95°C and
31 s at 60°C, with subsequent melting curve analysis
increasing the temperature from 60 to 95°C.
The primers were designed using a Primer Express®
software (Applied Biosystems) and had the following
sequences: for adiponectin, sense 5'-CTGGCTTTCTTCT-
CTTCCATGATAC-3', and antisense 5'-GTGTCGACGTTC-
CATGATTCTC-3' (82-bp product); for UCP1, sense 5'-
TGGAGGTGTGGCAGTGTTCA-3', and antisense 5'-ATG-
GCTCTGGGCTTGCATT-3' (70-bp product); for UCP2,
sense 5'-CTGGTCGCCGGCCTGCAGCGC-3', and antisense
5'-GATCCCTTCCTCTCGTGCAAT-3' (273-bp product);
and for β-actin, sense 5'-TAGCCACCTTCCAGCAGATGT-
3', and antisense 5'-AGCTCAGTAACAGTCCGCCTA-3'
(101-bp product). Relative quantification of gene expression
with real-time PCR data was calculated relative to β-actin.
Data analysis
All statistical analysis was performed with the Statcel 2
software package (OMS publishing Inc., Saitama, Japan).
We used one-way ANOVA with a Scheffe-type multiple
comparison test to compare several parameters among four
groups. All data are expressed as the means ± SE, and p
values <0.05 were considered statistically significant.
Results
Effects of BOF and DAI on body weight and WAT weight
There was no significant difference in food intake among
groups; the mean was 8.0 g/day/body at the first week of the
experiment. Throughout the experimental period of 4 weeks,
no significant differences in mean body weight were
observed among the four groups of mice given the four
different diets (Table 3). The weight of WAT, which was
composed of perirenal, epididymal, mesenteric and inguinal
adipose tissues, was higher in the HF group (high-fat diet-
fed mice) than in the BD group (basal diet-fed normal mice).
The wet weights of the perirenal, epididymal, mesenteric,
and inguinal WAT of the HF + BOF group were 75%, 89%,
85%, and 70%, respectively, of those in the HF group. The
ratio of WAT/body weight was significantly higher in the HF
group compared with that in the BD group (Table 3). The
increase in the WAT/body weight ratio in the HF group was
significantly inhibited in the HF + BOF group, but not
affected in the HF + DAI group.
Effects of BOF and DAI on the size of white adipocytes
The histological findings of WAT in each group are shown
in Fig. 1A. The adipocytes in the HF group were larger than
those in the BD group. The average size of adipocytes in
WAT was increased by >200% in the HF group. The increase
in adipocyte size was significantly reduced in the HF + BOF
group, but not in the HF + DAI group (Fig. 1B).
Effects of BOF and DAI on mRNA expression of adiponectin
and its plasma levels
No significant differences were observed among the four
groups of mice in adiponectin mRNA expression in WAT
(Fig. 2). The plasma levels of adiponectin tended to decrease
in the HF group compared to the BD group, but not signifi-
cantly. There were no statistically significant differences in
plasma adiponectin levels between the HF group and the
HF + BOF group (Table 4).
mRNA expression of UCP1 and UCP2 in WAT and BAT
There were no significant differences in UCP-1 mRNA
Table 4.P lasma levels of adiponectin
The data are expressed as the means ± SE of 5–6 mice.
Group Plasma adiponectin (µg/ml)
Basal diet (BD) 19.43 ± 2.86
High-fat (HF) diet 17.20 ± 1.34
HF + BOF 19.33 ± 2.28
Table 3. Effects of bofu-tsusho-san (BOF) and dai-saiko-to (DAI) on body weight and white adipose tissue, liver, and kidney weights
The data are expressed as the means ± SE of 5–6 mice. 
#p<0.05 as compared with the BD group and +p<0.05 as compared with the HF group.
Group
Body weight 
(g)
White adipose tissue weight (g) WAT/BW × 100 
(%)
liver weight 
(g)
Kidney weight 
(g) perirenal epididymal mesenteric inguinal
Basal diet (BD) 31.5 ± 0.5 0.55 ± 0.04 1.22 ± 0.10 0.97 ± 0.08 0.92 ± 0.03 11.6 ± 0.6 1.52 ± 0.06 0.40 ± 0.02
High-fat (HF) diet 32.2 ± 0.8 0.65 ± 0.05 1.33 ± 0.07 1.12 ± 0.08 1.23 ± 0.11 13.4 ± 0.7# 1.20 ± 0.05 0.41 ± 0.02
HF + BOF 31.1 ± 0.6 0.49 ± 0.01 1.19 ± 0.07 0.95 ± 0.05 0.87 ± 0.04 11.2 ± 0.3+ 1.18 ± 0.05 0.44 ± 0.02
HF + DAI 32.3 ± 0.6 0.62 ± 0.03 1.40 ± 0.09 1.11 ± 0.07 1.22 ± 0.08 13.4 ± 0.6 1.23 ± 0.04 0.43 ± 0.01S. Akagiri et al.
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expression of BAT among the four groups (Fig. 3A). The
expression of UCP-1 mRNA was significantly increased in
WAT in the HF + BOF group, but there was little expression
of UCP-1 mRNA in the BD, HF, or HF + DAI groups
(Fig. 3B). There were no significant differences in UCP2
mRNA expression in BAT or WAT among the four groups
(Fig. 4).
Effects of BOF and DAI on oral glucose tolerance test
Blood glucose levels at 30 min and 60 min after glucose
loading were elevated to >200 mg/dl (Fig. 5A) in all groups.
The elevated glucose levels and increased glucose AUC in
the HF group tended to decrease in the HF + BOF group, but
not significantly (Fig. 5A, B).
Fig. 1. Representative histological findings of white adipose tissues (A) and the size of white adipocytes (B) of mice fed a purified
powdered diet (BD), a purified high-fat powdered diet (HD), a high-fat diet plus bofutsushosan (HF + BOF), or a high-fat diet
plus daisaikoto (HF + DAI). The data are expressed as the means ± SE of 5–6 mice. #p<0.05 compared with the BD group and
+p<0.05 compared with the HF group.
Fig. 2. Adiponectin mRNA expression levels of the epididymis
adipose tissue of mice fed a purified powdered diet
(BD), a purified high-fat powdered diet (HD), a high-fat
diet plus bofutsushosan (HF + BOF), or a high-fat diet
plus daisaikoto (HF + DAI). The data are expressed as
the means ± SE of 5–6 mice.
Fig. 3. Uncoupling protein 1 (UCP1) mRNA levels of brown
adipose tissue (A) and white adipose tissue (B) of mice
fed a purified powdered diet (BD), a purified high-fat
powdered diet (HD), a high-fat diet plus bofutsushosan
(HF + BOF), or a high-fat diet plus daisaikoto
(HF + DAI). The data are expressed as the means ± SE
of 5–6 mice.Bofutsushosan and Obesity
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Effects of BOF and DAI on serum lipids
The serum levels of lipids (LDL cholesterol, triglyceride,
and non-esterified fatty acid) tended to increase in the HF
group compared with those in the BD group. The treatment
with BOF did not affect these lipid levels (Table 5).
Effects of BOF and DAI on blood pressure and heart rate
Because adrenergic pathway is involved in the reaction of
Chinese medicine used, blood pressure and heart rate were
measured. There were no significant differences in blood
pressure or heart rate among groups (Table 6).
Discussion
In the present study, the ratio of WAT/body and the size of
adipocytes were significantly increased in the HF group
compared with those in the BD group, and these increases
were significantly inhibited by the treatment with BOF, but
not DAI. This anti-obesity action of BOF was consistent
with the previous reports using other models of obesity [10,
20]. In addition, no significant differences were observed
among the four groups of mice given the different diets in
the mean whole body, liver, or kidney weights throughout
the experimental period of 4 weeks. There were no signifi-
cant differences in plasma lipid profile, serum ALT level as
an index of hepatic injury, or BUN as an index of renal
injury between the HF group and the HF + BOF group.
These data suggest the possibility that the fat mass-lowering
effect of BOF is not due to the toxicity of the Kampo
medicine but rather to a direct pharmacological action on
adipose tissues.
Obesity is a common risk factor for type 2 diabetes and
cardiovascular disease, because adipose tissue secretes
several factors that contribute to the development of such
pathologies. In the present study, we first measured the
changes in serum adiponectin concentration and adiponectin
mRNA expression in WAT, because adiponectin mRNA
expression and adiponectin plasma levels was reported to
be significantly reduced in obese/diabetic mice [21] and
humans [22]. However, no significant differences were
observed among the groups in serum adiponectin concentra-
tion or adiponectin mRNA expression in WAT. Our previous
study using this model demonstrated that mRNA expression
Fig. 4. Uncoupling protein 2 (UCP2) mRNA levels of brown
adipose tissue (A)and white adipose tissue (B) of mice
fed a purified powdered diet (BD), a purified high-fat
powdered diet (HD), a high-fat diet plus bofutsushosan
(HF + BOF), or a high-fat diet plus daisaikoto
(HF + DAI). The data are expressed as the means ± SE
of 5–6 mice. +p<0.05 compared with the HF group.
▲
Fig. 5. Oral glucose tolerance test (A) and area under the curve (AUC) glucose (B) of mice fed a purified powdered diet (BD), a
purified high-fat powdered diet (HD), a high-fat diet plus bofutsushosan (HF + BOF), or a high-fat diet plus daisaikoto
(HF + DAI). The data are expressed as the means ± SE of 5–6 mice.S. Akagiri et al.
J. Clin. Biochem. Nutr.
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of adiponectin in WAT was markedly decreased beginning at
8 weeks in the high-fat diet-fed mice [8]. The present study
also demonstrated that the BOF treatment tended to decrease
the blood glucose levels after glucose loading and to
decrease glucose AUC compared with that in the HF group.
However, these differences did not reach the levels of
statistical significance. In the future, it will be necessary to
investigate the effects of BOF treatment on adiponectin
expression or glucose tolerance in a study with a longer
follow-up.
BAT has been implicated as an important site for
facultative energy expenditure in small rodents, because of
its capacity for uncoupled mitochondrial respiration. UCP1
expression in BAT is also known as a significant component
of whole body energy expenditure and its dysfunction
contributes to the development of obesity [15]. However,
there was no significant difference in UCP1 mRNA expres-
sion of BAT among the four groups in this study. Thus, the
decrease in WAT found in the HF + BOF group could not be
explained only by the energy expenditure in BAT mito-
chondria by UCP1. However, if the expression of UCP1 can
be activated in tissues other than BAT by Kampo ingredients,
this could constitute a good therapy for obesity. In the
present study, UCP1 mRNA in WAT was barely detectable
in the BD and HF groups, whereas significant expression
was found in the HF + BOF group. A number of studies
have shown that β-3 adrenoreceptor agonists induce
expression of UCP1 not only in BAT, but also WAT. Indeed,
the appearance of brown adipocyte-like cells in WAT upon
stimulation of β-3 adrenoreceptors has been reported [16,
23–26]. Inokuma et al. [16] have clearly demonstrated that
the anti-obesity effect of β-3 adrenogenic stimulation is
largely attributable to UCP1 in BAT and ectopically
expressed in WAT, but is less attributable to UCP2 and
UCP3, and thereby to UCP1-dependent degradation of fatty
acids released from WAT. In addition, it has been suggested
that the release of norepinephrine, a β-3 adrenoreceptor
agonist, can be stimulated by the ephedrine [27] contained in
Ephedrae Herba, which is found in BOF, not in DAI. It
has been reported that 1 g of BOF contains 3.33 mg of l-
ephedrine and 0.73 mg of d-pseudoephedrine [10], and it
has also been demonstrated that ephedrine reduces the
weight of WAT and increases energy expenditure in mono-
sodium-L-glutamate-induced obese mice. Therefore, BOF
containing ephedrine is considered to reduce the weight of
WAT by enhancing the thermogenic anti-obesity effect of
ephedrine.
In conclusion, we found that a diet supplemented with
BOF inhibited the visceral fat accumulation in high-fat
diet-fed mice, and that BOF induced gene expression of
UCP1, which regulates energy metabolism in WAT. Our
results suggest that BOF exerts anti-obesity properties.
Recently, a randomized, double-blind clinical trial showed
that BOF improved visceral adiposity and insulin resistance
Table 5. Effects of bofutsushosan (BOF) on serum levels of lipid, ALT, and BUN
The data are expressed as the means ± SE of 5–6 mice.
Basal diet High-fat diet High-fat diet + BOF
ALT U/l 26 ± 13 14 ± 82 2 ± 13
Free cholesterol mg/dl 22 ± 41 8 ± 42 0 ± 0
LDL cholesterol mg/dl 150 ± 36 218 ± 63 238 ± 52
HDL cholesterol mg/dl 54 ± 25 93 ± 31 137 ± 39
Triglyceride mg/dl 94 ± 39 122 ± 84 182 ± 23
Non-esterified fatty acid µeq/l 1178 ± 583 1680 ± 358 2114 ± 757
BUN mg/dl 19 ± 31 9 ± 31 8 ± 3
Table 6. Blood pressure and heart rate of mice fed a purified powdered diet (BD),
a purified high-fat (HF) powdered diet, a high-fat diet plus bofutsushosan
(HF + BOF), or a high-fat diet plus daisaikoto (HF + DAI).
The data are expressed as the means ± SE of 5–6 mice.
Group
Blood pressure (mmHg) Heart rate 
(/min) Systolic Mean
Basal diet (BD) 120.4 ± 1.9 76.4 ± 2.4 716 ± 30
High-fat (HF) diet 115.4 ± 2.8 74.4 ± 3.1 715 ± 35
HF + BOF 113.5 ± 3.7 70.3 ± 3.7 735 ± 64
HF + DAI 110.0 ± 3.8 69.8 ± 3.9 735 ± 47Bofutsushosan and Obesity
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in obese women with impaired glucose tolerance [9]. Further
studies are needed to evaluate the effect of BOF on thermo-
genesis and UCP1 expression in human WAT.
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